Thomas M. Ross - Net Worth and Insider Trading

Thomas M. Ross Net Worth

The estimated net worth of Thomas M. Ross is at least $0 dollars as of 2024-05-16. Thomas M. Ross is the EVP, Global Sales & Marketing of MaxCyte Inc and owns about 0 shares of MaxCyte Inc (MXCT) stock worth over $0. Details can be seen in Thomas M. Ross's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Thomas M. Ross has not made any transactions after 2023-04-12 and currently still holds the listed stock(s).

Transaction Summary of Thomas M. Ross

To

Thomas M. Ross Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Thomas M. Ross owns 1 companies in total, including MaxCyte Inc (MXCT) .

Click here to see the complete history of Thomas M. Ross’s form 4 insider trades.

Insider Ownership Summary of Thomas M. Ross

Ticker Comapny Transaction Date Type of Owner
MXCT MaxCyte Inc 2023-04-12 EVP & Global Sales

Thomas M. Ross Latest Holdings Summary

Thomas M. Ross currently owns a total of 1 stock. Thomas M. Ross owns 0 shares of MaxCyte Inc (MXCT) as of April 12, 2023, with a value of $0.

Latest Holdings of Thomas M. Ross

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
MXCT MaxCyte Inc 2023-04-12 0 4.80 0

Holding Weightings of Thomas M. Ross


Thomas M. Ross Form 4 Trading Tracker

According to the SEC Form 4 filings, Thomas M. Ross has made a total of 9 transactions in MaxCyte Inc (MXCT) over the past 5 years, including 0 buys and 9 sells. The most-recent trade in MaxCyte Inc is the sale of 14,134 shares on April 12, 2023, which brought Thomas M. Ross around $70,670.

Insider Trading History of Thomas M. Ross

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Thomas M. Ross Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Thomas M. Ross Ownership Network

Ownership Network List of Thomas M. Ross

No Data

Ownership Network Relation of Thomas M. Ross


Thomas M. Ross Owned Company Details

What does MaxCyte Inc do?

Who are the key executives at MaxCyte Inc?

Thomas M. Ross is the EVP & Global Sales of MaxCyte Inc. Other key executives at MaxCyte Inc include director & President and CEO Douglas Doerfler , Chief Financial Officer Douglas J Swirsky , and 10 percent owner Casdin Partners Master Fund, L.p. .

MaxCyte Inc (MXCT) Insider Trades Summary

Over the past 18 months, Thomas M. Ross made 6 insider transaction in MaxCyte Inc (MXCT) with a net sale of 145,666. Other recent insider transactions involving MaxCyte Inc (MXCT) include a net sale of 360,000 shares made by Douglas Doerfler , a net sale of 60,000 shares made by John Joseph Johnston , and a net purchase of 80,000 shares made by Richard Douglas .

In summary, during the past 3 months, insiders sold 10,000 shares of MaxCyte Inc (MXCT) in total and bought 0 shares, with a net sale of 10,000 shares. During the past 18 months, 565,666 shares of MaxCyte Inc (MXCT) were sold and 80,000 shares were bought by its insiders, resulting in a net sale of 485,666 shares.

MaxCyte Inc (MXCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

MaxCyte Inc Insider Transactions

No Available Data

Thomas M. Ross Mailing Address

Above is the net worth, insider trading, and ownership report for Thomas M. Ross. You might contact Thomas M. Ross via mailing address: C/o Maxcyte, Inc., 22 Firstfield Road, Suite 110, Gaithersburg Md 20878.

Discussions on Thomas M. Ross

No discussions yet.